Credit Suisse Ag Exelixis, Inc. Call Options Transaction History

Credit Suisse Ag

3 transactions

Quarter	Operation	Price Per call	calls change	calls Held
Q4 2020 Feb 12, 2021	SELL	$18.39 - $24.8 $7.59 Million - $10.2 Million	-412,800 Reduced 87.46%	59,200 $1.19 Million
Q4 2018 Feb 13, 2019	BUY	$13.65 - $21.8 $6.03 Million - $9.64 Million	442,000 Added 1473.33%	472,000 $9.28 Million
Q3 2018 Nov 13, 2018	BUY	$15.87 - $22.4 $476,100 - $672,000	30,000 New	30,000 $532,000

460

246M

1.7M

1.02M

Ticker EXEL
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 321,832,000
Market Cap $7.07B
Description
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...

Get notified when there are updates to the investment portfolio of Credit Suisse Ag, based on Form 13F filings with the SEC.

Stay updated on Credit Suisse Ag with notifications on news.